NCT05691985Completed
Fib to Alb Ratio in Type 2 Dkd
Fibrinogen to Albumin Ratio (FAR) as a Risk Factor for Type 2 Diabetic Nephropathy(DN)
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
Aimed to investigate the association of fibrinogen to albumin ratio (FAR) with DKD type 2 and to prove its possible role as a novel biomarker to predict and prevent DKD progression.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 11 Jan 2023
- Start date
- 25 Jul 2024
- Primary completion date
- 12 Mar 2025
- Lead sponsor
- Assiut University
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT05691985
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 25 Jul 2024 to the primary completion date, 12 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pts with ESKD, manifested cardiac valvular disease, acute infection, history of hepatitis, pts with DKA and Cancer.
Age
- Age below 18 yrs.
Other
- Pt who refused to contribute in this study
Who the study is looking for
- Age above 18 yrs.
- 50 Pts with type 2 DM that have DKD (presence of albuminuria in association with diabetic retinopathy) and 50 pts with type 2 DM but have no DKD.
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine Assiut University Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.